Publications - NEO 212
Understanding The Pharmacokinetic Properties Of NEO 212
Pharmacokinetic Properties of the Temozolomide Perillyl Alcohol Conjugate (NEO212) in Mice. Authors: Thomas C Chen, M.D., PhD 1,4, Hee-Yeon Cho1, Steve Swenson1, Thu Zan Thein1, Weijun Wang1, Neloni R. Wijeratne2, Nagore I. Marín-Ramos1, Jonathan E. Katz2, Florence M....
NEO 212 Enhances Temozolomide’s Ability To Increase Radiosensitivity And Cytotoxicity In Glioblastoma Tumors
Developing A Clinically Relevant Radiosensitizer For Temozolomide-Resistant Gliomas. Authors: Radu O. Minea1, Tuan Cao Duc2, Stephen D. Swenson1, Hee-Yeon Cho1, Mickey Huang3, Hannah Hartman4, Florence M. Hofman5, Axel H. Schonthal4and Thomas C. Chen1,5 A new study...
Further NEO 212 Studies Shows Ability To Slow GBM Cell Invasion at Sub-Cytotoxic Dose
NEO 212 Sub-Cytotoxic Doses Capable of Inhibiting Glioma Stem Cell Invasion. Authors: Thomas C. Chen1, Nagore I. Marín-Ramos1, and Florance M. Hofman2 Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by its extensive vascularity, aggressiveness,...
NEO 212 Inhibits Migration and Invasion of Glioma Stem Cells
A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo. Authors: Thomas C. Chen1,2, Hee-Yeon Cho1, Weijun Wang1, Manasai Barath3, Natasha Sharma4, Florance...
NEO 212 Shown To Downregulate Production of MGMT For Treatment Of Non-Small Cell Lung Cancer
Temozolomide–perillyl alcohol conjugate downregulates O6- methylguanin DNA methltransferase via inducing ubiquitination-dependent proteolysis in non-small cell lung cancer (NSCLC). Authors: Xingguo Song1, Li Xie1,2, Minghui Chang2,3, Xinran Geng4, Xingwu Wang1, Thomas...
Studying The Therapeutic Effect Of NEO 212 Nasopharyngeal Carcinoma
Therapeutic Effect Of TMZ-POH On Human Nasopharyngeal Carcinoma Depends On Reactive Oxygen Species Accumulation Authors: Li Xie1, Xingguo Song1, Wei Guo2, Xingwu Wang1, Ling Wei1, Yang Li1, Liyan Lv1, Weijun Wang3, Thomas C. Chen3, and Xianrang Song1 NeOnc...